<DOC>
	<DOCNO>NCT02570035</DOCNO>
	<brief_summary>This purpose study investigate effect mirabegron cardiovascular system patient overactive bladder current history cardiovascular disease .</brief_summary>
	<brief_title>Specified Drug Use-results Survey Betanis Tablets Patients With Coexisting Cardiovascular Disease</brief_title>
	<detailed_description />
	<mesh_term>Cardiovascular Diseases</mesh_term>
	<mesh_term>Urinary Bladder , Overactive</mesh_term>
	<mesh_term>Mirabegron</mesh_term>
	<criteria>coexist cardiovascular disease history cardiovascular diseases electrocardiogram record conduct within seven day start mirabegron treatment ( include first day administration ) serious cardiovascular disease significant long QT ( QTc &gt; 500 msec )</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>Mirabegron</keyword>
	<keyword>Overactive Bladder</keyword>
	<keyword>Cardiovascular Disease</keyword>
</DOC>